נטליזומאב - Natalizumab

נטליזומאב - Natalizumab
התוויות	Tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . To delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. The safety and efficacy of Tysabri beyond two years are unknown. Because Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability, Tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. Safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.

דרך מתן

נטליזומאב - Natalizumab
שמות מסחריים	®TYSABRI


קבוצה פרמקולוגית (ATC)	"SELECTIVE IMMUNOSUPPRESSIVE AGENTS"
שם גנרי	"נטליזומאב" (קישור לדף התרופה במאגר משרד הבריאות)
סל הבריאות	כלול
התוויות	Tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . To delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. The safety and efficacy of Tysabri beyond two years are unknown. Because Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability, Tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. Safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.
שם יצרן	BIOGEN IDEC INC., USA
שם בעל הרישום	MEDISON PHARMA LTD
עלון לרופא	"עלון לרופא באנגלית"